{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-101531","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2026-08-26T20:30:04+00:00","discovered_at":"2026-08-26T20:31:00.185681+00:00","generated_at":"2026-08-26T20:31:35.034933+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Phibro Animal Health reports record FY2026 results, raises FY2027 guidance","bullets":["Q4 net sales $396.7M (+5% YoY); diluted EPS $0.53 (+26%); adjusted EPS $0.85 (+35%).","FY2026 net sales $1,518.1M (+17%); net income $99.7M; adjusted EBITDA $255.0M (+39%).","FY2027 guidance: net sales $1.55-1.60B, adjusted EBITDA $258-268M, adjusted net income $140-147M.","Plans to close Chicago Heights manufacturing facility; production ceases summer 2027, ~100 employees affected.","Regulatory uncertainty on virginiamycin in Brazil; guidance assumes minimal sales, potential upside if approved."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-101531","json":"https://secwatch.observer/filing/0001104659-26-101531.json","markdown":"https://secwatch.observer/filing/0001104659-26-101531.md","text":"https://secwatch.observer/filing/0001104659-26-101531.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926101531/0001104659-26-101531-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926101531/pahc-20260826x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-26T20:31:35.034933+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}